GlassScriptPhysician profile
Claude W Gilbreath
NPI 1356324594
$14,874.84
in general payments reported to CMS, 2019-2025
55 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,190 · 2020: $2,525 · 2021: $2,533 · 2022: $2,203 · 2023: $2,204 · 2024: $1,676 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,423.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,082.85 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,364.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,330.99 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $1,286.56 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,176.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,044.63 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $753.85 | 2019-2025 | Trintellix |
| Pfizer INC. | $576.76 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $545.07 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Bayer Healthcare Pharmaceuticals INC. | $365.50 | 2022-2025 | |
| Amarin Pharma, INC. | $314.88 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $297.87 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.95 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $295.12 | 2019-2023 | Dificid |
| Sanofi-Aventis U.S. LLC | $267.25 | 2019-2021 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Gilbreath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.